pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·Jul 15·1 min read
save

Agentic AI poised to reshape clinical development by moving beyond tools to autonomous decision-making

Jul 15, 2026·read at Fierce Biotech ↗Positive

Earlier this year, a colleague argued that clinical leaders should stop asking whether they have an 'AI strategy', because the question often leads to the wrong conversation.

Instead, leaders are urged to evaluate how AI can predict important outcomes, optimize processes, and automate tasks that improve clinical development performance.

The term 'agentic AI' refers to systems that do more than generate answers; they can assess information, decide next steps, interact with tools, and adapt to changing conditions to achieve a defined goal.

New products, announcements and demonstrations of agentic AI are appearing almost weekly, signaling a shift from experimentation to implementation in the biotech sector.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “Understanding Agentic AI in Clinical Development”

read at Fierce Biotech ↗
1,613 words · retrieved Jul 20
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING
topics
Ophthalmology

related stories

  • Jul 28An eye drug biotech banks $118M and stocks its executive suiteBioPharma Dive
  • Jul 28STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATDSTAT
  • Jul 27Sarepta names former AbbVie R&D exec Michael Severino as next CEOBioSpace
  • Jul 27Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEOBioPharma Dive
  • Jul 27Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drugFierce Biotech